Gilead Sciences Inc.'s said Friday in pre-market trade that chairman and 20-year chief executive officer John Martin will become the company's executive chairman, effective March 10. He will be replaced by president and chief operating officer John Milligan, who will become CEO and join the company's board of directors. The biopharmaceutical company's stock was down 2.5% in light pre-market trade.
Continue Reading Below
Copyright © 2016 MarketWatch, Inc.